Program
PA9159
A development code. Also written as “PA9159 nasal spray solution, 80 μg one day treatment”, “PA9159 Metered-Dose Inhaler, 120 μg per day for 28 days” and “PA9159 nasal spray solution, 160 μg one day treatment”.
Its studies are mostly in Asthma · Rhinitis, Allergic · Rhinitis, Allergic, Seasonal, led by Anhui Palo Alto Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Anhui Palo Alto Pharmaceuticals | 62 open or running | phase 2since Feb 1, 2022 | Sep 28, 2021 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 28, 2021First study: phase 1 study in Rhinitis, AllergicFirst studyNCT05170763 · 60 enrolled · China
- Feb 1, 2022Phase 2 study in Rhinitis, AllergicNCT05234580 · 204 enrolled · China
- Mar 12, 2025Phase 1 study in AsthmaNCT06916273 · 40 enrolled · China
- Dec 23, 2025Phase 1 study in Rhinitis, AllergicNCT07345442 · 36 enrolled · China
- Dec 23, 20252 phase 2 studies in AsthmaNCT07326995, NCT07324707
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07324707Asthma · China | 2 | Recruiting | Mar 2026 | 30 |
| NCT07345442Rhinitis, Allergic · China | 1 | Completed | Jun 9, 2025 | 36 |
| NCT07326995Asthma · China | 2 | Recruiting | Feb 2026 | 60 |
| NCT06916273Asthma · China | 1 | Completed | Sep 12, 2024 | 40 |
| NCT05234580Rhinitis, Allergic · China | 2 | Completed | Oct 10, 2022 | 204 |
| NCT05170763Rhinitis, Allergic · China | 1 | Completed | Jan 5, 2022 | 60 |
How it is read
Names in the registry
- “PA9159 nasal spray solution, 80 μg one day treatment”, 2 entries
- “PA9159 Metered-Dose Inhaler, 120 μg per day for 28 days”, 2 entries
- “PA9159 nasal spray solution, 160 μg one day treatment”, 1 entry
- “PA9159 nasal spray solution, 320 μg one day treatment”, 1 entry
- “PA9159 nasal spray solution, 80 μg 7-day treatment”, 1 entry
Codes read as this program: PA9159.
Conditions, from the studies’ own filings
- Asthma, 3 studies
- Rhinitis, Allergic, 2 studies
- Rhinitis, Allergic, Seasonal, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.